The most accessible consumer tVNS device — strong on protocol variety and price, lighter on independent clinical evidence.
Best for consumers who want guided neck-worn tVNS with protocol variety, at an accessible price.
Pulsetto is a Lithuanian-made neck-worn tVNS collar that stimulates the cervical vagal branches transcutaneously through two electrode pads. It runs four guided programmes — sleep, stress, anxiety reduction, pain reduction — through a companion app. CE-marked as a wellness device. The clearest entry point into consumer tVNS at the price; the evidence base is mostly company-sponsored and early.
How we tested: Evidence-based assessment — scored from manufacturer specifications, the published Pulsetto pilot record and independent 2026 reviews. Not hands-on tested by ONDA.
+Four guided programmes — broadest protocol variety in the category
+Cheapest neck-worn tVNS at $269
+Companion app logs sessions and tracks self-rated state
+CE-marked; documented pulse parameters
Cons
−Independent clinical evidence is thinner than Nurosym or gammaCore
−Saline/gel pads need regular replacement
−Premium features locked behind Pulsetto+ subscription
−No on-device HRV biofeedback
Price: $269 one-time; optional Pulsetto+ subscription ~$8/mo (as of 2026-05-21)
Where it leads
Pulsetto is the easiest way into consumer cervical tVNS. The neck-worn collar makes daily use simple — no clip to fiddle with, no handheld to hold against the carotid — and the app drives four distinct programmes (sleep, stress, anxiety, pain) instead of asking the user to titrate intensity themselves. At $269 it is also the cheapest cervical device in this list, and the parameters are documented inside the app rather than hidden.
Where it falls short
The trade-off is evidence. Most of the supporting research is company-sponsored or in pilot stage; the deeper randomised-trial base belongs to Nurosym and gammaCore. The neck pads need periodic saline or gel-pad replacement, which adds friction. And the more sophisticated features — additional programmes, deeper insights — sit behind the Pulsetto+ subscription, so the $269 ticket understates the full ownership cost a little.
Who it is for
Choose Pulsetto if you want a polished daily-use cervical tVNS device with structured programmes and minimal setup, and you are comfortable with a lighter independent-evidence base in exchange for accessibility. If clinical-grade evidence is the deciding criterion, Nurosym is the right pick. If you want a one-time-purchase device with no app subscription, Truvaga 350 is closer to that shape.
Background reading
The biology behind what these devices target — and the protocols that compound with the hardware.